The Prime Minister today participated in the first-ever Quad leaders’ meet which was attended by US President Joe Biden, Australian Prime Minister Scott Morrison and Japanese PM Yoshihide Suga.
Had fruitful discussions with @POTUS @JoeBiden, PM @ScottMorrisonMP and PM @sugawitter at the 1st Quad Summit. Re… https://t.co/LKMSldfpPY
— Narendra Modi (@narendramodi) 1615567736000
“Our discussions today on vaccines, climate change, and emerging technologies make the Quad a positive force for global good and for peace, stability and prosperity in the Indo-Pacific,” the Prime Minister said on Twitter after the summit.
Modi said that during the summit, the group launched a landmark partnership to ensure accessibility of Covid-19 vaccines.
United in our fight against COVID-19, we launched a landmark Quad partnership to ensure accessibility of safe COVID… https://t.co/PLk0YZTFG7
— Narendra Modi (@narendramodi) 1615567737000
“United in our fight against COVID-19, we launched a landmark Quad partnership to ensure accessibility of safe COVID-19 vaccines. India’s formidable vaccine production capacity will be expanded with support from Japan, US & Australia to assist countries in the Indo-Pacific region,” he said.
Modi said he also reiterated India’s commitment to a free, open and inclusive Indo-Pacific in line with the vision of SAGAR – Security and Growth for All in the Region.
Had fruitful discussions with @POTUS @JoeBiden, PM @ScottMorrisonMP and PM @sugawitter at the 1st Quad Summit. Re… https://t.co/LKMSldfpPY
— Narendra Modi (@narendramodi) 1615567736000
Addressing a press conference after the virtual summit, foreign secretary Harsh Vardhan Shringla said the vaccine initiative “is the most pressing and valuable” among the concrete takeaways of the first summit meeting of Quad leaders.
He said that the four-member countries have agreed to pool their financial resources, manufacturing capabilities and logistics to ramp up the manufacture and distribution of vaccines in the Indo-Pacific region.
Shringla said the aim is to produce a billion doses by the end of 2022.
(With inputs from agencies)